By Fineline Cube 
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196) announced that the Shenzhen Biopharmaceutical Industry Fund will participate in a Series A financing of its controlling subsidiary, Fosun Kairos. The fund will invest up to RMB 600 million in tranches, subscribing for no more than RMB 524,437,452 of new registered capital in FosunKairos. Proceeds will finance operations and business development of Fosun Kairos and/or its subsidiaries.
Company & Financial Snapshot
| Item | Detail |
|---|---|
| Investor | Shenzhen Biopharmaceutical Industry Fund |
| Investment | RMB 600 million (tranches) |
| Capital Commitment | Up to RMB 524,437,452 |
| Pre‑Money Valuation | RMB 2.2 billion |
| Use of Funds | Operations & business development of FosunKairos & subsidiaries |
Fosun Kairos – A Pioneer in Cell‑Therapy
- Founded – April 2017
- Core Focus – R&D, manufacturing, and commercialization of cell‑therapy products
- Flagship Product – Axicabtagene Ciloleucel Injection (first CAR‑T therapy approved for marketing in China)
Approved Indications (as of 17 Oct 2025)
- Relapsed or refractory large B‑cell lymphoma (r/r LBCL) after ≥ 2 lines of systemic therapy
- LBCL refractory to first‑line chemoimmunotherapy or relapsing within 12 months of first‑line therapy
Ongoing Program – Third indication (relapsed/refractory indolent non‑Hodgkin lymphoma) in bridging clinical trial phase; included in China’s Breakthrough Therapy Designation program (excluding HK, Macau, TW).
Strategic Impact
- Capital Infusion – Enables accelerated development of next‑generation CAR‑T and other cell‑therapy platforms.
- Market Positioning – Strengthens Fosun Kairos’ leadership in China’s rapidly expanding cell‑therapy market.
- Investor Confidence – The Shenzhen fund’s commitment underscores confidence in FosunKairos’ pipeline and commercial strategy.
Forward‑Looking Statements
This release contains forward‑looking statements that involve risks and uncertainties. Actual results may differ materially.-Fineline Info & Tech